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ABSTRACT 
Peptide Conjugated Lipid Nanoparticles and their role on Cancer Drug Delivery are reviewed here. The benefits of nanotechnology and 
combination style of medicine delivery are still hindered without the active ligands needed for treatment efficacy. This work analyzes the role of 
peptide ligands in different forms of cancer treatments targeting cells and tissues.  
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Introduction 
The process of self-assembly results in the formation of 
micro and nanoscale structures that find application in 
cancer therapy because of their unique and tunable 
nanostructures. While combination chemotherapeutics and 
nanotechnology are indeed useful for targeted drug delivery 
and improved treatment efficacy, a challenge continues to 
exist in the form of active targeting ligand that can be used1-7. 
This work is a review of peptides like the peptide conjugated 
lipid nanoparticles that are used in cancer treatment 
delivery. 
Peptide-conjugated Lipid Nanoparticles 
Sun et al. analyzed the effects of using peptide ligand 
structures for Doxorubicin DOX drug delivery in the case of 
breast cancer treatment and lymphoma treatment8-14. 
Traditionally, although DOX was effective for breast cancer 
treatment, the cardiotoxicity concerns necessitated the 
research into finding more suitable alternatives for drug 
delivery. Nanotechnology-enabled better ways of 
administration where drugs were directed to the tumor site. 
Selective accumulation at the site was possible because of 
how nanotechnology created better permeability and 
retention. Sun et al15. propose a solution for active targeting 
ligands in the form of an RGD peptide ligand. The peptide 
ligand assured safety and delivered DOX into the targeted 
cells efficiently16-24. 
Cheng et al. in their evaluation of peptide-conjugated lipid 
nanoparticles as DDS in lung and cervical carcinomas were 
able to identify that T7 peptide conjugating caused a more 
enhanced cellular uptake of the tumor cell targeting lipid 
nanoparticles (LNPs) than the non-targeted LNPs. 
Chemotherapeutic drugs are used to treat lung cancer. Drugs 
such as paclitaxel are used as part of an effective treatment 
plan. However, they have a range of side effects and limited 
efficacy25. The antisense oligonucleotides ASOs are 
particularly useful for target gene translation and for 
modulating programmed cell death. However, ASOs face 
challenges as well. Some of them suffer nuclease degradation 
or have a low permeability. Off-target effects result in 
increased cytotoxicity15,26-30. Target binding affinity is low 
which means more drug would be needed to ensure that the 
target cells are reached. In this context, the use of the T7 
peptide helps in providing high affinity, and hence better 
tumor cell targeting is achieved. Cheng et al21 assessed the 
efficiency rates of the drug in their studies. The authors 
conducted both in vitro and in vivo studies. They were able 
to identify that the T7 ligand attachment to the surface was 
efficient than non-conjugated LNPs. The overall anti-tumor 
activity of the conjugated peptides was hence stronger. More 
survival time was noticed in the mice considered as part of 
the study, and furthermore, the effective targeted action will 
be helpful in reducing cytotoxicity31-34.  
Peptide-conjugated nanoparticles are useful for the targeted 
imaging and therapy of prostate cancer. In the development 
of anti-cancer drugs, it has been identified that many 
medications are not that efficient. In-vitro biopanning helped 
Yeh et al.35 to identify those peptide phages that will be 
useful as an anti-cancer treatment. Peptides are short-chain 
amino acid monomers. The peptide or the amide bond links 
the short chain monomers. As they form longer chains, the 
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protein structure is visible. On the other hand, as just short 
chains, they signal cells. This aspect of specific peptide 
phages is used for targeting prostate cancer cells. Target 
specific action was analyzed by researchers Yeh et al.35 using 
the ELISA and the flow cytometry method. The authors made 
use of doxorubicin and vinorelbine. The purpose of peptide 
conjugated nanoparticles is hence more efficient in 
treatment delivery and effects. Tumor targeting ability as 
tested with a xenograft model supports this assessment36,37. 
In addition to targeting tumors, and delivering drugs to the 
site of needed action, the peptides are useful for enhancing 
drug effects as well. The phages helped deliver drugs to the 
end target which is the tumor. These targeting effects were 
validated in a xenograft model, in which a high accumulation 
of targeting phage was observed.  
Peptide-conjugated nanoparticles are active for the targeted 
therapy of various ways of cancer and different forms of 
treatment. Research on the use of peptide conjugated 
nanoparticles was conducted by Yu et al. where the authors 
made use of them in antiangiogenic cancer therapy. 
“Angiogenesis plays a critical role in the growth of cancer 
because solid tumors need a blood supply if they are to grow 
beyond a few millimeters in size. Tumors can cause this 
blood supply to form by giving off chemical signals that 
stimulate angiogenesis. Tumors can stimulate nearby normal 
cells to produce angiogenesis signaling molecules”. Tumor 
cells could cause the formation of new blood vessels whose 
sole activity is to support the cancer cells, and this helps the 
cancer cells proliferate faster to form new cancer cell 
clusters (the process of metastases). Thus, in the context of 
cancer, anti-angiogenesis refers to the inhibition of the 
formation of those new vessels that make the cancer cells 
thrive. The researchers used a drug delivery system DDS 
where the nanoparticles conjugated with the peptides6-13. 
The size of the conjugated nanoparticles made it easier for 
those particles to be assimilated and internalized within the 
human umbilical vein and expected antiangiogenic activity 
occurred. This antiangiogenic activity targeted the tumor’s 
neovasculature structure, cutting off its blood supply. This 
leads to the death of the tissues, such as the necrosis of the 
tissues. Thus, the use of nanoparticulate peptide-based DDS 
strategies could aid in targeted necrosis and apoptosis of 
cancer cells and tissues as compared to other forms of drug 
delivery.  
Conclusion 
The work sought to present the role of Peptide-conjugated 
Lipid Nanoparticles on Anti-Cancer Drug Delivery. Secondary 
research review was conducted, and the different ways that 
lipid nanoparticles and ligand structures are used for 
improving transportation of the drug to target sites are 
assessed.  
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